BerandaAMLX • NASDAQ
add
Amylyx Pharmaceuticals Inc
$3,49
Setelah Jam Perdagangan Normal:(0,00%)0,00
$3,49
Tutup: 27 Jan, 16.02.00 GMT-5 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$3,60
Rentang hari
$3,45 - $3,66
Rentang tahun
$1,58 - $19,95
Kapitalisasi pasar
299,05 jt USD
Volume Rata-Rata
889,69 rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Sep 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 416,00 rb | -99,59% |
Biaya operasional | 17,83 jt | -63,41% |
Laba bersih | -72,70 jt | -447,98% |
Margin laba bersih | -17,48 rb | -85.981,67% |
Penghasilan per saham | -1,07 | -456,67% |
EBITDA | -75,44 jt | -496,59% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (USD) | Sep 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 234,40 jt | -33,98% |
Total aset | 250,71 jt | -46,27% |
Total liabilitas | 54,51 jt | 13,13% |
Total ekuitas | 196,20 jt | — |
Saham yang beredar | 68,55 jt | — |
Harga terhadap nilai buku | 1,26 | — |
Tingkat pengembalian aset | -64,90% | — |
Tingkat pengembalian modal | -81,67% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Sep 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -72,70 jt | -447,98% |
Kas dari operasi | -41,57 jt | -704,22% |
Kas dari investasi | 38,82 jt | 135,91% |
Kas dari pembiayaan | 80,00 rb | -91,00% |
Perubahan kas bersih | -2,44 jt | 97,83% |
Arus kas bebas | -86,18 jt | -1.426,30% |
Tentang
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024. Wikipedia
Didirikan
2013
Situs
Karyawan
384
